The evidence for immunotherapy in dermatomyositis and polymyositis: a systematic review

Clinical Rheumatology

Volumn 34, Issue 12, 2015, Pages 2089-2095

  Vermaak, Erin ^a,b   Tansley, Sarah L ^a,c   McHugh, Neil J ^a,c  

^a ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BATH   (United Kingdom)

Author keywords

Dermatomyositis; DMARD; Immunotherapy; Polymyositis; Randomised controlled trial; Systematic review

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOGLOBULIN; LYMPHOCYTE ANTIBODY; METHOTREXATE; MUSCLE ENZYME; RITUXIMAB; BIOLOGICAL PRODUCT; CORTICOSTEROID; CYCLOSPORIN; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; DERMATOMYOSITIS; DRUG SAFETY; DRUG TOLERABILITY; ELECTROMYOGRAM; EVALUATION STUDY; FOLLOW UP; HUMAN; IMMUNOTHERAPY; LEUKAPHERESIS; META ANALYSIS; MUSCLE BIOPSY; MUSCLE STRENGTH; PHYSICAL ACTIVITY; PLASMAPHERESIS; POLYMYOSITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME; EVIDENCE BASED MEDICINE; PRACTICE GUIDELINE;

ADRENAL CORTEX HORMONES; AZATHIOPRINE; BIOLOGICAL PRODUCTS; CYCLOSPORINE; DERMATOMYOSITIS; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; LEUKAPHERESIS; METHOTREXATE; PLASMAPHERESIS; POLYMYOSITIS; PRACTICE GUIDELINES AS TOPIC; RITUXIMAB; TREATMENT OUTCOME;

EID: 84947487019     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-015-3059-y     Document Type: Article

References (29)

1. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical research ed). 339:b2700
2. Higgins JPT GS. Cochrane Handbook for Systematic Reviews of Interventions: The Cochrane Collaboration; 2011. Available from: www.cochrane-handbook.org
3. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347
4. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407
5. Dalakas MC (1991) Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 325:1487–1498
6. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12
7. Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM et al (2004) International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 50:2281–2290
8. Gordon PA, Winer JB, Hoogendijk JE, Choy EH (2012) Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Sys Rev 8:CD003643
9. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65:314–324
10. Ibrahim F, Choy E, Gordon P, Dore CJ, Hakim A, Kitas G, et al. (2014) Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids. Rheumatology
11. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C et al (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993–2000
12. Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL et al (1998) Treatment of refractory myositis. A randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 41:392–399
13. van de Vlekkert J, Hoogendijk JE, de Haan RJ, Algra A, van der Tweel I, van der Pol WL et al (2010) Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. Neuromuscul Disord 20:382–389
14. Miyasaka N, Hara M, Koike T, Saito E, Yamada M, Tanaka Y (2012) Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol 22:382–393
15. (2011) A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 70:427-36.
16. Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG (1980) Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Int Med 92:365–369
17. Vencovsky J, Jarosova K, Machacek S, Studynkova J, Kafkov J, Bartunkov J et al (2000) Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 29:95–102
18. Hollingworth P, de Vere TA, Ansell BM, Platts-Mills T, Gumpel JM, Mertin J et al (1982) Intensive immunosuppression versus prednisolone in the treatment of connective tissue diseases. Ann Rheum Dis 41:557–562
19. Amemiya K, Semino-Mora C, Granger RP, Dalakas MC (2000) Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 94:99–104
20. Bunch TW (1981) Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum 24:45–48
21. Miller FW, Leitman SF, Cronin ME, Hicks JE, Leff RL, Wesley R et al (1992) Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 326:1380–1384
22. Convery FR, Minteer MA, Amiel D, Connett KL (1977) Polyarticular disability: a functional assessment. Arch Phys Med Rehabil 58:494–499
23. Mahoney FI, Barthel DW (1965) Functional Evaluation: The Barthel Index. Maryland State Med J 14:61–65
24. (1996) The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group. Arch Neurology. 53:141-7
25. Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM et al (2014) Predictors of clinical improvement in rituximab-treated refractory adult and juvenile Dermatomyositis and adult polymyositis. Arthritis Rheum 66:740–749
26. Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE et al (1993) Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 94:379–387
27. Miller JWY, Saminaden S, Lecky BRF, Winer JB (2002) Randomised double blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. J Neurol Sci 199(Suppl 1):S53
28. Ruperto N, Pistorio A (2013) Knupp Feitosa de Oliveira S, Cuttica R, Ravelli A, Fischbach M, et al. A randomized trial in new onset juvenile dermatomyositis: prednisone versus prednisolone plus cyclosporine versus prednisone plus methotrexate. Pediatric. Rheumatology 11(Suppl 2):O19
29. Tansley SL, Sharp C, McHugh N, Christopher-Stine L, Chinoy H (2014) Developing Standardized Treatment for Adults with Myositis and Different Phenotypes. Rheumatology 53(suppl 1):i127